Immunoprecise Antibodies Ltd
IPA1.705USD
+0.065+3.96%
시장 운영 시간 （ET）시세는 15분 지연됩니다
78.69M시가총액
손실P/E TTM
자세한 내용은 Immunoprecise Antibodies Ltd 회사
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
회사 정보
종목 코드 IPA
회사 이름Immunoprecise Antibodies Ltd
상장일Jan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
직원 수- -
유형Ordinary Share
회계 연도 종료Jan 30
주소Industrious 823 Congress Ave Suite 300
도시AUSTIN
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호78701
전화16048060626
웹사이트https://www.ipatherapeutics.com/
종목 코드 IPA
상장일Jan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Dr. Ilse Roodink, Ph.D.
Dr. Ilse Roodink, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Director
Director
--
--
Mr. Barry A. Springer
Mr. Barry A. Springer
Independent Director
Independent Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Dr. Ilse Roodink, Ph.D.
Dr. Ilse Roodink, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Director
Director
--
--
수익 분석
통화: CAD마지막 업데이트: Sun, Jul 6
통화: CAD마지막 업데이트: Sun, Jul 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
사업별CAD
이름
수익
비율
Project revenue
5.57M
90.59%
Product sales revenue
501.00K
8.15%
Cryo storage revenue
78.00K
1.27%
지역별CAD
이름
수익
비율
United States of America
2.88M
46.90%
Europe
2.72M
44.19%
Australia
383.00K
6.23%
Other
112.00K
1.82%
Canada
53.00K
0.86%
사업별
지역별
사업별CAD
이름
수익
비율
Project revenue
5.57M
90.59%
Product sales revenue
501.00K
8.15%
Cryo storage revenue
78.00K
1.27%
주식 보유 통계
마지막 업데이트: Sat, Jul 12
마지막 업데이트: Sat, Jul 12
주주
주주 유형
주주
주주
비율
Charmquark TWEE
7.92%
Ingalls & Snyder LLC (Asset Management)
6.02%
Susquehanna International Group, LLP
1.52%
Bath (Jennifer Lynne)
1.08%
Two Sigma Investments, LP
0.20%
Other
83.26%
주주
주주
비율
Charmquark TWEE
7.92%
Ingalls & Snyder LLC (Asset Management)
6.02%
Susquehanna International Group, LLP
1.52%
Bath (Jennifer Lynne)
1.08%
Two Sigma Investments, LP
0.20%
Other
83.26%
주주 유형
주주
비율
Corporation
7.99%
Investment Advisor/Hedge Fund
6.14%
Investment Advisor
1.82%
Individual Investor
1.34%
Research Firm
0.35%
Hedge Fund
0.26%
Family Office
0.04%
Venture Capital
0.04%
Other
82.02%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
45
8.20M
23.19%
+1.46M
2025Q1
45
6.32M
13.81%
+742.61K
2024Q4
45
4.34M
9.53%
-1.30M
2024Q3
46
5.39M
19.68%
+72.87K
2024Q2
48
5.12M
19.96%
-156.62K
2024Q1
50
5.14M
20.20%
-196.19K
2023Q4
58
5.33M
20.96%
+124.72K
2023Q3
50
4.91M
19.67%
-438.42K
2023Q2
53
5.01M
20.08%
-885.29K
2023Q1
54
5.19M
20.83%
-561.90K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Charmquark TWEE
1.83M
4%
-1.30M
-41.62%
Dec 31, 2024
Ingalls & Snyder LLC (Asset Management)
2.76M
6.03%
+1.20M
+76.65%
Mar 31, 2025
Susquehanna International Group, LLP
703.00K
1.54%
+703.00K
--
Mar 31, 2025
Bath (Jennifer Lynne)
498.12K
1.09%
+237.30K
+90.98%
Dec 16, 2024
Two Sigma Investments, LP
90.58K
0.2%
+90.58K
--
Mar 31, 2025
Virtu Americas LLC
57.85K
0.13%
+37.09K
+178.66%
Mar 31, 2025
CIBC World Markets Inc.
41.20K
0.09%
--
--
Mar 31, 2025
Thoroughbred Financial Services LLC
40.00K
0.09%
+40.00K
--
Mar 31, 2025
Group One Trading, L.P.
30.06K
0.07%
+30.00K
+49180.33%
Mar 31, 2025
Levine (Mitchell S)
30.00K
0.07%
+10.00K
+50.00%
Aug 01, 2024
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
